Strategies for Maximizing the Value of Mature Drug Products

The global pharmaceutical industry is facing a looming patent cliff. Exclusivity rights for hundreds of medications are set to expire by 2030, including for “blockbuster” products. The fallout: lower-priced generics and biosimilars quickly flood the market whenever a drug product reaches the end of exclusivity, impacting large pharmaceutical companies’ sales and brands.

This industry outlook report explores these pressures, and the strategies large pharma companies are turning to fill top-line revenue gaps. A proactive approach can help biopharmaceutical companies make the most of their late-lifecycle assets — an approach that begins long before the end of exclusivity draws near. Highlights include:

• How expanding markets, indications, and patient populations can maximize late-lifecycle products.
• Extending the value of products and brands with strong potential in mass-market sales.
• The future of mature product lifecycle management and key benefits of outsourcing strategy.

​